NCT03033095View on ClinicalTrials.gov

Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

March 28, 2018

Conditions
Spondylitis, Ankylosing
Interventions
DRUG

Etanercept ® 50 mg

The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.

Trial Locations (1)

38043

University Hospital Grenoble, Grenoble

All Listed Sponsors
lead

University Hospital, Grenoble

OTHER

NCT03033095 - Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers | Biotech Hunter | Biotech Hunter